Preclinical studies in lung cancer show that the EGFR pathway enhances immunosuppression through increased engagement of PD-1/PD-L1 and CTLA4 in an ERK and NFkB dependent manner [107]. This evidence concerns the gene CTLA4 and lung cancer.